RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial ...
Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...
The complement system has more than 50 soluble and membrane-bound proteins. In innate and adaptive immunity, complement is essential for eliminating foreign pathogens and apoptotic cells. It is also ...
Complement activation is usually controlled by regulatory factors such as complement factor H (CFH) and alteration of this process causes severe diseases such as atypical haemolytic uraemic syndrome ...
In a recent study published in the Science Bulletin, researchers comprehensively examined the composition and phenotypic features of myeloid cells in human failing hearts at a single-cell level, ...
BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...
Achillion Pharmaceuticals, Inc.ACHN announced positive interim data from clinical studies evaluating its factor D inhibitors - ACH-4471, ACH-5228 and ACH-5548. Two phase II studies are evaluating the ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback